Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Connetics to resume Extina testing with new phase III trial
The company’s original application for Extina was turned down in the form of a non-approvable letter received in November 2004 due to insufficient clinical data. As a result
The company’s original application for Extina was turned down in the form of a non-approvable letter received in November 2004 due to insufficient clinical data. As a result
In early June, the same authority granted full reimbursement status for this orally available dual endothelin receptor antagonist. Tracleer(r) is being made available in Japan through Actelion’s own
Remoxy is a novel, abuse-resistant form of long-acting oxycodone, which is the active ingredient in popular but prone to abuse pain medication Oxycontin. The double-blind, randomized, multi-center phase
The firm will use OmniComm’s TrialMaster phase I application to collect data at phase I in-patient units. Laboratory data will be imported into the application in an attempt
Hematide is a peptide-based erythropoiesis stimulating agent (ESA) being developed for the treatment of anemia in patients with chronic kidney disease and cancer. Hematide is currently being evaluated
This consolidation is being undertaken to bring the company into compliance with the minimum bid requirements of Nasdaq. Hemosol believes that retaining its Nasdaq listing is of strategic
Preclinical studies using lung cancer cells have demonstrated, for the first time, that mda-7 protein binds to a critical cellular enzyme called PKR. The binding of mda-7 to
Endo’s drug, a bioequivalent version of Purdue’s OxyContin, does not infringe patent protection according to the court ruling. This affirmation allows Endo to launch the tablets in four
The company will sell 9.9 million shares of common stock at a price of $5.48 per share, together with warrants to purchase approximately 3.5 million additional shares of
The pre-clinical data suggests that Cardio Vascu-Grow significantly improves the healing rate of open wounds in a diabetic rodent model. Dr Jack Jacobs, CEO of Cardio said: “At